A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen estetrol - PubMed
4 days ago
- #estetrol
- #Relugolix
- #contraception
- New oral contraception concept using Relugolix (GnRH antagonist) and estetrol (fetal estrogen) from adolescence to perimenopause.
- Replaces progestins with Relugolix to suppress ovarian function, combined with low-dose estetrol.
- Key benefits: continuous amenorrhea, smooth perimenopausal transition, and reduced breast cancer risk due to absence of progesterone/progestins.
- Dubbed the 'RE4Women' concept, focusing on life cycle endocrine management.
- Phase 2 studies planned to determine optimal estetrol dose for different age groups (18-35 and 36-51 years).